Newspaper publication for unaudited financial results for quarter ended June 30, 2025.
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech has published its unaudited financial results for the quarter ended June 30, 2025 in Business Standard and Sakal newspapers on August 13, 2025, as required under SEBI Listing Regulations. On a consolidated basis, total income from operations rose sharply by about 79% year-on-year to ₹14,503.40 lakhs from ₹8,094.95 lakhs. The company swung to a consolidated profit after tax of ₹2,160.17 lakhs, compared to a loss of ₹593.30 lakhs in the same quarter last year. Standalone performance was similarly strong, with revenue up nearly 70% YoY to ₹12,785.95 lakhs and a profit after tax of ₹1,623.38 lakhs versus a loss of ₹485.03 lakhs. Consolidated basic EPS improved to ₹7.49 from a loss per share of ₹2.01, while standalone EPS rose to ₹2.38 from a loss of ₹0.54.
This is a strong turnaround quarter for Fermenta Biotech, with revenue nearly doubling and the company returning to healthy profitability after a loss in the year-ago period. Shareholders are likely to view the results positively, though the filing itself is a routine regulatory disclosure and the actual stock impact will depend on how the market had already priced in the August 12 results announcement.